Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.

چکیده

Tirzepatide, recently Food and Drug Administration (FDA) approved for weight loss, offers substantial metabolic benefits, yet its long-term impact on diabetic retinopathy (DR) remains unclear. The study purpose was to compare the risk of DR diagnoses, progression, and need for ocular interventions…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• رتینوپاتی دیابتی
• درمان های ضد VEGF